EF Hutton analyst Tony Butler initiated coverage of Compugen with a Buy rating and $13 price target. The clinical-stage biotech has an immune-oncology pipeline consisting of three clinical programs targeting immune checkpoints and the lead program, COM701, has shown utility as monotherapy and in combination with other checkpoint inhibitors, Butler tells investors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CGEN:
- Compugen to hold a conference call
- Compugen’s COM701 shows durable anti-tumor activity in ovarian cancer
- Compugen’s COM701 shows preliminary anti-tumor activity in ovarian cancer
- Compugen management to meet virtually with Oppenheimer
- Compugen price target lowered to $8 from $12 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com